Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Reports Pipeline Progress and 2017 Operating Results
Significant Operational and Financial Progress in 2017 with a Robust Set of Data and Events Expected in 2018 Mirvetuximab Soravtansine Phase 3 FORWARD I Trial to Complete Enrollment by Mid-Year; FORWARD II Combination Data to be Presented Throughout 2018 Novel ADC Pipeline Continues to Advance with
View HTML
Toggle Summary ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 6, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its 2017 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 26, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen Appoints Stuart A. Arbuckle to Board of Directors
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 24, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Stuart A. Arbuckle to its Board of Directors. Mr.
View HTML
Toggle Summary ImmunoGen Announces First Patient Dosed in Phase 1 Study of IMGN632 for Hematological Malignancies
Second ADC Using ImmunoGen’s Novel DNA-Alkylating Payloads to Enter the Clinic WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 4, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the first patient has
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation and Q&A at the 36th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 2, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, will present at the upcoming 36 th Annual J.P.
View HTML
Toggle Summary ImmunoGen Presents New Clinical and Preclinical Data at ASH Annual Meeting
CD33-Targeting IMGN779 Demonstrates Favorable Safety Profile and Anti-Leukemia Activity in Ongoing Phase 1 Trial; Dose Escalation Continues with Two Dosing Schedules Preclinical Data Presentations on IMGN779 in Combination and CD123-Targeting IMGN632 Highlight Breadth of ImmunoGen Hematology
View HTML
Toggle Summary ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: Jefferies 2017
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results
Collaboration with Jazz Pharmaceuticals Accelerates Development of Early-Stage ADC Assets and Strengthens Financial Position $100+ Million Follow-on Financing Provides Two-year Operating Runway Presentations Accepted for ASH Annual Meeting Highlight Potential of Novel IGN Portfolio IMGN632
View HTML
Toggle Summary ImmunoGen to Present New Data on Novel Antibody-Drug Conjugates at 59th ASH Annual Meeting
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that three abstracts highlighting two of the Company's experimental ADC therapies, IMGN632 and IMGN779, have been
View HTML